That is what lenacapavir offers. It is one of the most exciting developments in HIV prevention in recent years, particularly in Southern Africa, where HIV continues to affect millions of people and places a heavy burden on families and communities.
And people clearly want new prevention choices.
In Gauteng, demand for lenacapavir has been so strong that some health facilities temporarily ran short. By the end of July, almost 18,000 people had already started using it. The province subsequently received another 28,593 initiation packs to replenish supplies and expand access.
This is encouraging. But it also reminds us of something very simple: even the best medicine cannot help someone if it is not available when they arrive at the clinic.
For CATHCA, preventing HIV is about protecting life and human dignity, especially among people who are most vulnerable. New prevention options such as lenacapavir can play an important role in this, while we continue to reaffirm the Church’s call to responsible choices and to care for ourselves and one another.
But health innovation cannot end with the discovery of a new medicine.
It also means making sure medicines remain in stock. It means ensuring that someone living in a rural community has a fair chance of accessing the same advances as someone living near a large urban hospital. And it means giving people clear information so that they can make informed choices about their health.
Sometimes, innovation does not involve a new medicine at all.
In Botswana, for example, the Red Cross is working with communities to strengthen disease surveillance. Community volunteers and frontline workers are being equipped to recognise and report possible health threats early, helping connect communities with the formal health system before a problem becomes a larger emergency.
There is an important lesson here for all of us.
Community and faith-based organisations are often close to people whom formal health systems struggle to reach. A community health worker may notice that someone has stopped taking treatment. A parish or community organisation may hear that medicines are unavailable at a local clinic. A trained volunteer may notice an unusual pattern of illness and know where to report it.
These things may not sound as impressive as a new medicine or medical technology. But they can make the difference between an innovation existing on paper and actually changing someone’s life.
Catholic Social Teaching reminds us to pay particular attention to people who are poor, vulnerable or at risk of being left behind. That principle should also guide how we think about health innovation.
New medicines and technologies give us good reason for hope. But their success should not be measured only by what science has made possible.
It should also be measured by who benefits.
In the end, a health breakthrough only matters if it reaches people.
Imagine a medicine that can help prevent HIV with just two injections a year.
That is what lenacapavir offers. It is one of the most exciting developments in HIV prevention in recent years, particularly in Southern Africa, where HIV continues to affect millions of people and places a heavy burden on families and communities.
And people clearly want new prevention choices.
In Gauteng, demand for lenacapavir has been so strong that some health facilities temporarily ran short. By the end of July, almost 18,000 people had already started using it. The province subsequently received another 28,593 initiation packs to replenish supplies and expand access.
This is encouraging. But it also reminds us of something very simple: even the best medicine cannot help someone if it is not available when they arrive at the clinic.
For CATHCA, preventing HIV is about protecting life and human dignity, especially among people who are most vulnerable. New prevention options such as lenacapavir can play an important role in this, while we continue to reaffirm the Church’s call to responsible choices and to care for ourselves and one another.
But health innovation cannot end with the discovery of a new medicine.
It also means making sure medicines remain in stock. It means ensuring that someone living in a rural community has a fair chance of accessing the same advances as someone living near a large urban hospital. And it means giving people clear information so that they can make informed choices about their health.
Sometimes, innovation does not involve a new medicine at all.
In Botswana, for example, the Red Cross is working with communities to strengthen disease surveillance. Community volunteers and frontline workers are being equipped to recognise and report possible health threats early, helping connect communities with the formal health system before a problem becomes a larger emergency.
There is an important lesson here for all of us.
Community and faith-based organisations are often close to people whom formal health systems struggle to reach. A community health worker may notice that someone has stopped taking treatment. A parish or community organisation may hear that medicines are unavailable at a local clinic. A trained volunteer may notice an unusual pattern of illness and know where to report it.
These things may not sound as impressive as a new medicine or medical technology. But they can make the difference between an innovation existing on paper and actually changing someone’s life.
Catholic Social Teaching reminds us to pay particular attention to people who are poor, vulnerable or at risk of being left behind. That principle should also guide how we think about health innovation.
New medicines and technologies give us good reason for hope. But their success should not be measured only by what science has made possible.
It should also be measured by who benefits.
In the end, a health breakthrough only matters if it reaches people.
That is what lenacapavir offers. It is one of the most exciting developments in HIV prevention in recent years, particularly in Southern Africa, where HIV continues to affect millions of people and places a heavy burden on families and communities.
And people clearly want new prevention choices.
In Gauteng, demand for lenacapavir has been so strong that some health facilities temporarily ran short. By the end of July, almost 18,000 people had already started using it. The province subsequently received another 28,593 initiation packs to replenish supplies and expand access.
This is encouraging. But it also reminds us of something very simple: even the best medicine cannot help someone if it is not available when they arrive at the clinic.
For CATHCA, preventing HIV is about protecting life and human dignity, especially among people who are most vulnerable. New prevention options such as lenacapavir can play an important role in this, while we continue to reaffirm the Church’s call to responsible choices and to care for ourselves and one another.
But health innovation cannot end with the discovery of a new medicine.
It also means making sure medicines remain in stock. It means ensuring that someone living in a rural community has a fair chance of accessing the same advances as someone living near a large urban hospital. And it means giving people clear information so that they can make informed choices about their health.
Sometimes, innovation does not involve a new medicine at all.
In Botswana, for example, the Red Cross is working with communities to strengthen disease surveillance. Community volunteers and frontline workers are being equipped to recognise and report possible health threats early, helping connect communities with the formal health system before a problem becomes a larger emergency.
There is an important lesson here for all of us.
Community and faith-based organisations are often close to people whom formal health systems struggle to reach. A community health worker may notice that someone has stopped taking treatment. A parish or community organisation may hear that medicines are unavailable at a local clinic. A trained volunteer may notice an unusual pattern of illness and know where to report it.
These things may not sound as impressive as a new medicine or medical technology. But they can make the difference between an innovation existing on paper and actually changing someone’s life.
Catholic Social Teaching reminds us to pay particular attention to people who are poor, vulnerable or at risk of being left behind. That principle should also guide how we think about health innovation.
New medicines and technologies give us good reason for hope. But their success should not be measured only by what science has made possible.
It should also be measured by who benefits.
In the end, a health breakthrough only matters if it reaches people.